EFFECTS OF BICTEGRAVIR-EMTRICITABINE-TENOFOVIR ALAFENAMIDE ON CORONARY FLOW RESERVE IN STABLE HIV PATIENTS (B/F/TAF-CFR) - PILOT STUDY
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.
- 20 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 11 Sep 2018 New trial record